Medical/Pharmaceuticals
NORROY BIOSCIENCE Showcased 11 Research Presentations at EANM' 26, Advancing Radiopharmaceutical Innovation and Global Ecosystem Collaboration
WUXI, China, Nov. 5, 2026 /PRNewswire/ -- NORROY BIOSCIENCE (NORROY), a late-stage clinical biotechnology company focused on innovative targeted radiopharmaceuticals, today announced that its proprietary pipelines were featured in eight Top Rated Oral Presentations (TROP) and three e-posters at ...
2026-11-05 18:00
2121
Dizal to Present Latest Clinical Data at ASH 2026
* Golidocitinib monotherapy showed high and durable response in adults with secondary HLH, to be featured in an oral presentation. * Two oral presentations showing superior clinical benefits of birelentinib, as a single agent or in combination with a BCL2 inhibitor, in 1st line CLL/SLL SHANGH...
2026-11-05 16:16
1869
Harbour BioMed Appoints Ms. Vivian Feng as Head of External Collaboration
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 5, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced t...
2026-11-05 14:57
1836
Ivonescimab Receives NMPA Priority Review for First-Line Biliary Tract Cancer
HONG KONG, Nov. 4, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) today announced that ivonescimab in combination with chemotherapy for the first-line treatment of locally advanced or metastatic biliary tract cancer (BTC) has been granted Priority Review by China's National Medical Products Adm...
2026-11-05 12:19
2473
ONE OF THE WORLD'S FIRST PERSONALISED BRAIN STIMULATION STUDIES SHOWS PROMISE FOR SEVERE OCD WITH NUH AND NUS MEDICINE EXTENDING THE APPROACH TO DEPRESSION AND ANXIETY
Building on an established NUH–NUS Medicine collaboration, the work combines clinical expertise and cutting‑edge neuroimaging to improve outcomes for patients who have not responded to standard treatments SINGAPORE, Nov. 4, 2026 /PRNewswire/ -- Mental health treatments such as transcranial magne...
2026-11-05 08:05
1900
Lunit Presents AI-Powered Pathology Research in Ovarian and Bladder Cancers at SITC 2026
Studies with Labcorp and CellCarta identify proliferation-related tissue differences in HRD ovarian cancer and explore spatial immune features associated with immunotherapy response in bladder cancer SEOUL, South Korea, Nov. 4, 2026 /PRNewswire/ -- Lunit (KRX: 328130), a leading provider of AI f...
2026-11-04 22:00
2431
Crystal Pharmatech Completes ELDICO ED-1 Installation; Dedicated MicroED Now in Routine Service
Instrument operational at the Suzhou R&D center, with MicroED built into solid-form screening and results in as little as 48 hours SUZHOU, China, Nov. 4, 2026 /PRNewswire/ -- Crystal Pharmatech, a science-driven CRO/CDMO specializing in solid-state research, preformulation studies, and formulati...
2026-11-04 20:15
1494
TJ Biopharma Announces Publication of Plonmarlimab Phase 2 Results in the Journal of Hematology & Oncology
* Findings build on TJ Biopharma's pioneering work on GM-CSF as a therapeutic target in macrophage- and myeloid cell-driven inflammation * Phase 2 results show encouraging clinical responses and glucocorticoid-sparing potential in macrophage activation syndrome HANGZHOU, China, Nov. 4, 2026 /...
2026-11-04 18:00
2624
Minghui Pharmaceutical and ASKA Pharmaceutical Enter into Exclusive License Agreement for the IGF-1R Antibody in Japan
HANGZHOU, China, SHANGHAI and TOKYO, Nov. 4, 2026 /PRNewswire/ -- Minghui Pharmaceutical ("Minghui") and ASKA PharmaceuticalCo., Ltd. ("ASKA") today announced that they have entered into an exclusive license agreement for the development and commercialization of MHB018A in Japan. MHB018A is a no...
2026-11-04 14:30
2639
IASO Bio Hosts FUCASO Singapore Launch Event, Marking the Official Commercial Landing of China's Original Fully Human BCMA CAR-T Cell Therapy in Southeast Asia's Healthcare Hub
IASO Bio and its Singapore partner Pills and Pokes jointly hosted the FUCASO launch event in Singapore on November 3, marking the official commercial arrival of the world's first fully human BCMA-targeted CAR-T cell therapy in Singapore. FUCASO was approved by Singapore's Health Sciences Authorit...
2026-11-04 12:59
2065
WuXi Biologics Receives Double Honors at 2026 HERA for ESG Reporting and Environmental Excellence
HONG KONG, Nov. 3, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced it received two Grand Awards at the ninth Hong Kong ESG Reporting Awards (HERA), winning Best ESG Report (Large-Cap) and Excell...
2026-11-04 12:44
1484
Samsung Biologics Achieves 'Negligible Risk' Rating in Sustainalytics ESG Assessment
* Earns ESG Risk Rating score of 9.0, ranking among the top 0.5% in the pharmaceuticals industry * Advances from 'Low Risk' to 'Negligible Risk,' the lowest ESG risk category * Recognition reflects continued improvements in ESG risk management across operations INCHEON, South Korea, Nov. 3, ...
2026-11-04 07:30
2074
Zuellig Pharma Strengthens Clinical Sourcing Capabilities in China through Strategic Acquisition
The acquisition of our newly licensed Hangzhou facility establishes robust local sourcing capabilities to accelerate and support clinical trials across China HANGZHOU, China, Nov. 3, 2026 /PRNewswire/ -- Zuellig Pharma, a leading healthcare solutions company in Asia, announced the strategic acqu...
2026-11-04 07:00
1766
MoleculeMind's New MMDesign Technical Report Demonstrates 94.7% Campaign Success Rate Across Diverse Molecular Targets and Modalities
SHANGHAI, Nov. 3, 2026 /PRNewswire/ -- MoleculeMind
2026-11-03 23:00
5532
140th Canton Fair Phase 3 Highlights Intelligent Healthcare Innovations for a Better Life
GUANGZHOU, China, Nov. 3, 2026 /PRNewswire/ -- Phase 3 of the 140th Canton Fair, held from October 31 to November 4, centers on the theme "Better Life." As health remains central to high quality of life, the Intelligent Healthcare Zone has emerged as a focal point for buyers seeking solutions tha...
2026-11-03 14:29
3254
POMDOCTOR LIMITED Announces Receipt of Nasdaq Notifications Regarding Continued Listing Requirements
GUANGZHOU, China, Nov. 2, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (Nasdaq: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today announced that on October 28, 2026, it received two letter...
2026-11-03 05:05
2408
Neurophet and RapidAI Partner to Expand Access to Alzheimer's and MS Treatment Monitoring
- Agreement expands Neurophet's reach into U.S. health systems and builds on RapidAI's leadership in enterprise clinical AI and neurosciences SEOUL, South Korea, Nov. 2, 2026 /PRNewswire/ -- Neurophet, an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, ...
2026-11-02 22:00
2582
Ractigen Therapeutics Kicks Off Multi-Center Phase II Clinical Trial of First-in-Class saRNA Therapeutic RAG-01 for Non-Muscle Invasive Bladder Cancer
* Trial initiated at Fudan University Shanghai Cancer Center (FUSCC) under the leadership of Leading Principal Investigator Professor Ding-Wei Ye, uniting 11 premier urologic oncology centers across China * Phase II study incorporates a safety run-in phase with a subsequent multi-cohort desig...
2026-11-02 21:25
2266
InventisBio Announces Topline Results of a Phase III Study of Nomelcitinib (TYK2 Inhibitor), Demonstrating Promising Efficacy and Safety in Patients with Moderate to Severe Plaque Psoriasis.
SHANGHAI, Nov. 2, 2026 /PRNewswire/ -- InventisBio Co., Ltd. today announced that itsJH2 selective TYK2 inhibitor nomelcitinib (D-2570) has met both the primary endpoint and the key secondary endpoint in a registrational Phase III clinical trial for the treatment of moderate-to-severe plaque psor...
2026-11-02 19:00
3523
Zhimeng Biopharma has completed the patients enrollment of its investigational drug, CB03-154, in the pivotal Phase 2/3 ALS clinical trial.
SHANGHAI, Oct. 31, 2026 /PRNewswire/ -- Shanghai Zhimeng Biopharma, Inc. ( "Zhimeng Biopharma")announced today that its independently developed next-generation potassium channel opener, CB03-154, intended for the treatment of amyotrophic lateral sclerosis (ALS), has successfullycompleted patient ...
2026-10-31 13:00
7003
Week's Top Stories
Most Reposted
/C O R R E C T I O N - Autodesk, Inc./
[Picked up by 1321 media titles]
2026-10-29 01:23
TD Brings its Global Asset Management Businesses Under One Name
[Picked up by 1167 media titles]
2026-11-02 20:00Waters Launches AI-Powered Peak Integration Expanding its Suite of Premium AI Subscription Capabilities for Empower Software
[Picked up by 1148 media titles]
2026-10-28 20:30Piramal Pharma Limited Announces Results for Q2 and H1 FY27
[Picked up by 1084 media titles]
2026-10-28 03:28Fintech OPay Raises $304 Million Ahead of NYSE Debut: NYSE Content Update
[Picked up by 1079 media titles]
2026-10-30 22:34
Most Read
1B views since June: Coda and TikTok Gaming turn content into commerce
2026-11-02 09:35
58679
Airbrush Upgrades AI Image Enhancer With 16K Output and Batch Processing for Up to 50 Images
2026-11-03 02:00
53547
iQIYI Launches China's First AI Film Studio in Shanghai, with Inaugural Title "Cop in Trouble" in Production
2026-11-02 09:52
51743
Korean Derma Skincare Brand MDP+ Launches at Nordstrom
2026-11-03 00:30
21187
Lorikeet Dreamweaver enables businesses to give every customer an AI account manager
2026-11-04 22:00
16459